Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1685-1693

  Leyland Jones, Brian ^a   Lennon, Sian ^a   Barton, Claire ^a   Banken, Ludger ^a   Gianni, Luca ^a   Marty, Michel ^a   Baselga, José ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DECISION MAKING; DISEASE COURSE; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 63749132329     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.8351     Document Type: Article

References (41)

1. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
2. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
3. Wolff AC, Hammond MEH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
4. Menard S, Fortis S, Castiglioni F, et al: HER2 as a prognostic factor in breast cancer. Oncology 61:67-72, 2001(suppl 2)
5. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
6. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
7. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer thathas progressed after chemotherapyfor metastatic disease. J Clin Oncol 17:2639-2648, 1999
9. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
10. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792,2001
11. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
13. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
14. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(AC→T) with doxorubicin and cyclophosphamide followed by do-cetaxel and trastuzumab(AC→TH) with docetaxel, carboplatin and trastuzumab(TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:2005(suppl 1; abstr 1)
15. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
16. Codony-Servat J, Albanell J, Lopez-Talavera JC, et al: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196-1201, 1999
17. Payne RC, Allard JW, Anderson-Mauser L, et al: Automated assay for HER-2/neu in serum. Clin Chem 46:175-182, 2000
18. Krainer M, Brodowicz T, Zeillinger R, et al: Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54:475-481,1997
19. Molina R, Jo J, Filella X, et al: C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19:2551-2555, 1999
20. Mori S, Mori Y, Mukaiyama T, et al: In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81:489-494, 1990
21. Isola JJ, Holli K, Oksa H, et al: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73:652-658,1994
22. Mehta RR, McDermott JH, Hieken TJ, et al: Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy. J Clin Oncol 16:2409-2416, 1998
23. Fornier MN, Seidman AD, Schwartz MK, et al: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastu-zumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234-239, 2005
24. Colomer R, Llombart-Cussac A, Lluch A, et al: Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15:201-206,2004
25. Kostler WJ, Schwab B, Singer CF, et al: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10:1618-1624, 2004
26. Kostler WJ, Steger GG, Soleiman A, et al: Monitoring of serum Her-2/neu predicts histopatho-logical response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 24:1127-1130, 2004
27. Imoto S, Kitoh T, Hasebe T: Serum c-erB-2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol 29:336-339, 1999
28. Baselga J, Carbonell X, Castafieda-Soto N-J, et al: Phase II study of efficacy, safety, and pharma-cokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162-2171,2005
29. Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastu-zumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003
30. Bianchi G, Albanell J, Eiermann W, et al: Pilot trial of trastuzumab starting with or after the doxo-rubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9:5944-5951, 2003
31. Ali SM, Esteva FJ, Fornier M, et al: Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol 24:3s, 2006(suppl; abstr 500)
32. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
33. Valero V, Roche H, Pienkowski T, et al: BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer. J Clin Oncol 25:37s,2007(abstr 1020)
34. Moreno-Aspitia A, Dueck AC, Lingle WL, et al: Serum HER2(sHER2) levels in early-stage HER2 neu(+) breast cancer(HER2 + BC): Results from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 26:13s, 2008(suppl; abstr 529)
35. Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab(Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749, 2001
36. Nahta R, Esteva FJ: Herceptin: Mechanisms of action and resistance. Cancer Lett 232:123-138,2006
37. Muller V, Witzel I, Luck HJ, et al: Prognostic and predictive impact of the HER-2/neu extracellular domain(ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86:9-18, 2004
38. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003
39. Schondorf T, Hoopmann M, Warm M, et al: Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem 48:1360-1362, 2002
40. Duffy MJ, Duggan C, Keane R, et al: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559-563, 2004
41. Given M, Scott M, McGrath JP, et al: The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 9:277-280, 2000